Snail-Induced Epithelial-to-Mesenchymal Transition Enhances P-gp-Mediated Multidrug Resistance in HCC827 Cells

Takumi Tomono1, Kentaro Yano2, Takuo Ogihara1

  • 1Laboratory of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, 60 Nakaorui-machi, Takasaki-shi, Gunma 370-0033, Japan.

Insights

Overexpression of Snail triggers epithelial-to-mesenchymal transition (EMT), leading to activation of P-glycoprotein (P-gp). This pathway enhances cancer cells' resistance to chemotherapy drugs, contributing to multidrug resistance (MDR).

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • P-glycoprotein (P-gp) mediates anticancer drug efflux, contributing to multidrug resistance (MDR).
  • Epithelial-to-mesenchymal transition (EMT), driven by Snail overexpression, enhances cancer cell migration and invasion.

Purpose of the Study:

  • To investigate if Snail-induced EMT influences P-gp expression and activity.
  • To elucidate the molecular mechanisms linking EMT and P-gp activation.

Main Methods:

  • Overexpression of Snail in cancer cells.
  • Analysis of epithelial and mesenchymal markers (E-cadherin, occludin, claudin-1, vimentin, ZEB1).
  • Western blot analysis for P-gp expression.
  • P-gp functional assays using rhodamine123 and paclitaxel.
  • Assessment of caveolin-1 phosphorylation and GRB2 expression.

Main Results:

  • Snail overexpression induced EMT markers.
  • P-gp expression levels remained similar, but P-gp activity increased in Snail-overexpressing cells.
  • Snail-overexpressing cells exhibited increased viability in the presence of paclitaxel.
  • Decreased caveolin-1 phosphorylation and GRB2 expression were observed in Snail-overexpressing cells.

Conclusions:

  • Snail induces EMT and activates P-gp, contributing to cancer MDR.
  • A novel pathway involving decreased GRB2-mediated caveolin-1 phosphorylation leads to P-gp activation during EMT.
  • Findings suggest new therapeutic strategies targeting EMT and P-gp activation in cancer treatment.